The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis

Martin Skov(Aarhus University), Thomas Holm Pedersen(Aarhus University), Eva R. Chin(Cytokinetics (United States)), Geert Jan Groeneveld(Leiden University Medical Center), W. David Arnold(University of Missouri Health System), Marieke L. de Kam(Centre for Human Drug Research), Ole Bækgaard Nielsen(Aarhus University), Anders Findsen(Aarhus University), Jorge A. Quiroz(Aarhus University), Jan J.G.M. Verschuuren(Leiden University Medical Center), Arthur H.M. Burghes(The Ohio State University Wexner Medical Center), Titia Q. Ruijs(Leiden University Medical Center), Kamilla Løhde Tordrup Dybdahl(Aarhus University), Nicholas M. Kelly(Aarhus University), Marianne Skals(Aarhus University), Lars J. S. Knutsen, Claus Olesen(Aarhus University), Thomas Skjærlund Grønnebæk(Aarhus University), Anders Riisager(Aarhus University), Martin Broch‐Lips(Aarhus University), Jeanette J. Morgen(Aarhus University), Jules A. A. C. Heuberger(Centre for Human Drug Research), Jeppe Blichfeldt Winther(Aarhus University), Nete Huus(Aarhus University), Jane Bold(Aarhus University), Thomas K. Petersen(Aarhus University), Klaus Gjervig Jensen(Aarhus University), Martijn R. Tannemaat(Leiden University Medical Center), John B. Hutchison(Babraham Institute), Catherine M.K.E. de Cuba(Leiden University Medical Center)
Science Translational Medicine
March 20, 2024
Cited by 31


Related Papers